[Featured Stock] Synergy Innovation Rises on Spotlight as Supplier of Microbial Culture Media to Samsung Biologics
[Asia Economy Reporter Minwoo Lee] Synergy Innovation's stock price is on the rise. Amid a global shortage of culture media necessary for manufacturing COVID-19 vaccines, news that the company is supplying microbial culture media to Samsung Biologics has gained attention.
As of 10:20 AM on the 21st, Synergy Innovation's stock price recorded 3,415 KRW, up 7.56% compared to the previous day. The positive news appears to be the supply of microbial culture media to Samsung Biologics, which is reportedly close to securing a contract for the contract manufacturing of Moderna's messenger RNA (mRNA) COVID-19 vaccine.
According to industry sources, Samsung Biologics is expected to finalize the contract for mRNA COVID-19 contract manufacturing with Moderna in Washington, USA, during President Moon Jae-in's visit to the United States for the Korea-US summit. Producing the Moderna vaccine requires having microbial culture facilities. Consequently, there is a global shortage of cell culture media.
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- "While Others Rest"...3 Million May Have to Work on the Alternative Public Holiday
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
In this situation, Synergy Innovation, the leading domestic supplier of microbial culture media and a supplier to Samsung Biologics, Celltrion, Seoul Asan Medical Center, and Samsung Seoul Hospital, is receiving attention.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.